death-rates for workers who spent at least a month at IBM chip-manufacturing plants.
"If the material is worthy,and the editor is satisfied the piece meets the journal's scientific standards, the publisher's interference smacks of censorship," says Clinics contributor Daniel Teitelbaum, a medical toxicologist at the Colorado School of Mines in Golden. "This is precisely the problem presented by Elsevier's refusal to publish the Clapp-Johnson paper."
Standing firm
Joseph LaDou, the guest editor of the Clinics issue on the electronics and semiconductor industries, which is scheduled for publication in November, adds: "We are standing together with Clapp and Johnson. We will publish when they publish, wherever that may be." LaDou, who is director of the International Center for Occupational Medicine at the University of California, San Francisco, says that the paper had passed muster with four peer-reviewers drawn from among the issue's contributors.
He adds that on 6 June, the day that Elsevier informed him that the Clapp-Johnson paper would not be published, he called on the journal's contributors to consider withholding their pieces from publication. By 9 June, seven of the nine contributors had agreed to withhold their papers. LaDou had also agreed to be an expert witness in the lawsuit, although the plaintiffs' lawyers did not call on him. The suit was decided in favour of IBM by a jury in February. The judge did not allow the data, and the conclusions drawn from them by Clapp and Johnson, to be presented to the jury, writing that they do "not and cannot demonstrate that there is any connection between the results of the study and exposure to chemicals at IBM". Some 200 similar lawsuits against the company are still in process.
But Clapp says that the broad pattern demonstrated by the huge database is important. He referred questions on the court order to his attorney,Indira Talwani.She says that IBM failed to mark as 'confidential' the deposition containing the study and Clapp's lengthy discussion of it with IBM lawyers. As a result, the plaintiffs' lawyers sent it to The New York Times, which published details of it last September. In addition, she says, any citizen may access the deposition containing the study at the Santa Clara County courthouse. "The stuff is in the public domain now, because IBM didn't take the right steps,"she says.
Clapp initially withdrew the paper from Clinics in March, after being warned by an IBM lawyer not to publish it, Talwani says. But he resubmitted it after taking legal advice and concluding that IBM no longer had the legal right to kept the study private. Scientists cry foul as Elsevier axes paper on cancer mortality A rash of lawsuits reflect concern over the safety of chip manufacture.
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